- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- BD, WHO partner to reduce labor-related complications in developing world
- CVS Caremark to stop selling tobacco in all store locations
- C&D gets FDA clearance for advanced pregnancy test kit, launches new app
GUILFORD, Conn. — Mitchell-Vance Labs this past fall launched a new scar product to add to its ScarAway lineup appealing to a whole other segment of women in search of scar therapy: ScarAway for C-sections.
The therapy will have direct appeal to 1-in-4 new mothers, which is the number of women who give birth by Cesarean section in the United States. In 2008, 1-in-3 moms delivered their babies by way of a C-section, according to the Centers for Disease Control and Prevention. The prevalence of the procedure has been on the rise since 1996, when 21% of all births were delivered via a C-section procedure.
The number of women either opting into or medically needing a C-section is expected to continue on its upward trajectory as more women experience childbirth later in life. In 1996, 32% of all women giving birth were between the ages of 40 and 54 years. In 2007, almost half (48%) of mothers giving birth fell into that age bracket.
The ScarAway product features an extended-length, medical-grade silicon scar sheet ideal for placement over that C-section cut, which is made just below the abdomen and right above the bikini line.